Skip to main content

Advertisement

SpringerLink
Log in

Evaluating the Effectiveness of Repricing for Market Expansion in the Japanese Drug Pricing System

  • Global Perspectives: Original Research
  • Published:
Therapeutic Innovation & Regulatory Science Aims and scope Submit manuscript

Abstract

Background

In 1994, the “Repricing for Market Expansion” system (the repricing system) was introduced to the pharmaceutical market in Japan to improve the financial performance of the national health insurance system. In 2010, the “Reward Premiums for the Promotion of Innovative Drug Discovery and the Resolution of Off-Label Use Issue, Etc.” system (the reward system) was introduced to promote the development of new drugs. This study evaluates the effectiveness of these systems from an empirical perspective.

Method

The data set used in this study was created using publicly available information from the Ministry of Health, Labour and Welfare (MHLW) website and a market database maintained by IMS Japan Pharmaceutical Market Sales.

Results

Anticancer or immunomodulating drugs were the most frequently affected by the repricing system. The sales of similar drugs did not exceed double the sales forecast, and to begin with, the repricing system was not applied to these drugs, unintentionally reducing the profitability of pharmaceutical companies. In addition, we found that pharmaceutical expenditures have been steadily and significantly increasing, although this aspect is just one of the circumstances surrounding the Japanese pharmaceutical market.

Conclusions

On the basis of these results, we propose that the current repricing system be replaced with one using a market mechanism that can evaluate the value of drugs from an economic perspective and help improving the financial performance of the national health insurance system. We also suggest that the number of generic medications on the market in Japan be increased to a ratio equivalent to those of the US and EU. We hope that the perspectives on Japan’s unique drug pricing system obtained from this article are utilized by pharmaceutical companies in developing their businesses in Japan.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Danzon PM, Pauly MV. Health insurance and the growth in pharmaceutical expenditures. J Law Econ. 2002;45:587–613.

    Article  Google Scholar 

  2. Morgan SG. Prescription drug expenditures and population demographics. Health Serv Res. 2006;41:411–428.

    Article  Google Scholar 

  3. Kurosawa H, Tamura K. Japanese drug pricing system: how to balance innovation and the reimbursement system [in Japanese]. Nihon Yakurigaku Zasshi. 2012;139:260.

    Article  Google Scholar 

  4. Ministry of Health, Labour and Welfare. Conceptual diagram of repricing for market expansion. http://www.mhlw.go.jp/stf/shingi/2r98520000020zbe-att/2r98520000020zy6.pdf. Published January 25, 2012. Accessed April 7, 2016.

  5. Ministry of Health, Labour and Welfare. Requirements for repricing for market expansion. http://www.mhlw.go.jp/stf/shingi/2r9852000001tu6d-att/2r9852000001tupq.pdf. Published November 2, 2011. Accessed April 7, 2016.

  6. Grabowski HG, Vernon JM. Returns to R&D on new drug introductions in the 1980s. J Health Econ. 1994;13:383–406.

    Article  CAS  Google Scholar 

  7. Grabowski HG, Vernon JM. The determinants of pharmaceutical research and development expenditures. J Evol Econ. 2000;10:201–215.

    Article  Google Scholar 

  8. Kyle MK. Pharmaceutical price controls and entry strategies. Rev Econ Stat. 2007;89:88–99.

    Article  Google Scholar 

  9. Golec J, Hegde S, Vernon JA. Pharmaceutical R&D spending and threats of price regulation. J Financ Quant Anal. 2010;45:239–264.

    Article  Google Scholar 

  10. Nakamura H. Toward construction of Japan’s new drug pricing system: aiming at financially improving Japan’s national health insurance system and at stimulating R&D activities of innovative drugs in Japan. Iryo To Shakai. 2005;15:97–109.

    Article  Google Scholar 

  11. Takayama A, Narukawa M. Pharmaceutical pricing and reimbursement in Japan for faster, more complete access to new drugs. Ther Innov Regul Sci. 2016;50:361–367.

    PubMed  Google Scholar 

  12. Shibata S, Uemura R, Suzuki T. Factors that affect the acquisition of reward premiums for promotion of innovative drug discovery in Japan. Ther Innov Regul Sci. 2016;50:56–65.

    PubMed  Google Scholar 

  13. Shibata S, Uemura R, Suzuki T. Impact of premium rewards for the promotion of innovative drug discovery on the Japanese pharmaceutical market: an analysis by therapeutic area. Ther Innov Regul Sci. 2016;50:49–55.

    PubMed  Google Scholar 

  14. Shibata S, Uemura R, Suzuki T. Comparative analysis between the top-selling Japanese pharmaceutical market and those of the United States, the United Kingdom, France and Germany. Ther Innov Regul Sci. 2016;50:221–227.

    PubMed  Google Scholar 

  15. Newell RG, Jaffe AB, Stavins RN. The induced innovation hypothesis and energy-saving technological change. Q J Econ. 1999;114:907–940.

    Article  Google Scholar 

  16. Acemoglu D, Linn J. Market size in innovation: theory and evidence from the pharmaceutical industry. Q J Econ. 2004;119:1049–1090.

    Article  Google Scholar 

  17. Finkelstein A. Static and dynamic effects of health policy: Evidence from the vaccine industry. Q J Econ. 2004;119:527–564.

    Article  Google Scholar 

  18. Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics. 2003;21:89–103.

    Article  Google Scholar 

  19. Muramatsu N, Akiyama H. Japan: super-aging society preparing for the future. Gerontologist. 2011;51:425–432.

    Article  Google Scholar 

  20. Andersson K, Bergström G, Petzold MG, Carlsten A. Impact of a generic substitution reform on patients’ and society’s expenditure for pharmaceuticals. Health Policy. 2007;81:376–384.

    Article  Google Scholar 

  21. Riku J. Current situation for generic drugs in Japan. J Generic Med. 2005;2:219–231.

    Article  Google Scholar 

  22. Straus SE, Richardson WS, Glasziou P, Haynes RB. Evidence-Based Medicine: How to Practice and Teach EBM. London: Churchill Livingstone; 2000.

    Google Scholar 

  23. Ghosh AK. Evidence-based to value-based medicine. Ann Intern Med. 2005;142:952.

    Article  Google Scholar 

  24. Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med. 1994;331:650–55.

    Article  CAS  Google Scholar 

  25. Ikegami N, Ikeda S, Kawai H. Why medical care costs in Japan have increased despite declining prices for pharmaceuticals. Pharmacoeconomics. 1998;14:97–105.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Basic Biological Sciences, Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo, 105-8512, Japan

    Shoyo Shibata RPh & Takeshi Suzuki RPh, PhD

  2. Division of Basic Education, Faculty of Pharmacy, Keio University, Tokyo, Japan

    Ryotaro Uemura PhD

Authors
  1. Shoyo Shibata RPh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ryotaro Uemura PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takeshi Suzuki RPh, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takeshi Suzuki RPh, PhD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shibata, S., Uemura, R. & Suzuki, T. Evaluating the Effectiveness of Repricing for Market Expansion in the Japanese Drug Pricing System. Ther Innov Regul Sci 50, 751–758 (2016). https://doi.org/10.1177/2168479016652927

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/2168479016652927

Keywords

Search

Navigation